Factor H binding protein (FHbp) is part of two vaccines recently licensed for prevention of sepsis and meningitis caused by serogroup B meningococci. FHbp is classified in three phylogenic variant groups that have limited antigenic cross-reactivity, and FHbp variants in one of the groups have low thermal stability. In the present study, we replaced two amino acid residues, R130 and D133, in a stable FHbp variant with their counterparts (L and G) from a less stable variant. The single and double mutants decreased thermal stability of the amino-(N-) terminal domain compared with the wild-type protein as measured by scanning calorimetry. We introduced the converse substitutions, L130R and G133D, in a less stable wild-type FHbp variant, which increased the transition midpoint (T m ) for the N-terminal domain by 8 and 12°C; together the substitutions increased the T m by 21°C. We determined the crystal structure of the double mutant FHbp to 1.6 Å resolution, which showed that R130 and D133 mediated multiple electrostatic interactions. Monoclonal antibodies specific for FHbp epitopes in the N-terminal domain had higher binding affinity for the recombinant double mutant by surface plasmon resonance and to the mutant expressed on meningococci by flow cytometry. The double mutant also had decreased binding of human complement Factor H, which in previous studies increased the protective antibody responses. The stabilized mutant FHbp thus has the potential to stabilize protective epitopes and increase the protective antibody responses to recombinant FHbp vaccines or native outer membrane vesicle vaccines with overexpressed FHbp. Neisseria meningitidis | complement Factor H | site-specific mutagenesis | calorimetry | crystal structure F actor H binding protein (FHbp) is a key antigen in two multicomponent vaccines that have been licensed in the United States and/or the European Union for prevention of bacterial meningitis and sepsis caused by Neisseria meningitidis. FHbp is an important virulence factor, as it binds human Factor H (FH) (1) to the bacterial surface, which negatively regulates complement activation. FHbp is under immune selection (2) to preserve this virulence mechanism and thus exhibits a high degree of antigenic variation. More than 800 amino acid sequence variants have been identified to date (available in the public database at pubmlst.org/ neisseria/fHbp). The individual sequence variants can be classified in two subfamilies (3) or three variant groups (4) based on amino acid sequence identity. Antibodies to FHbp from variant group 1 do not elicit complement-mediated bactericidal activity against strains with FHbp from variant groups 2 or 3 and vice versa; therefore, it has been proposed that two or more divergent FHbp antigens are needed to achieve broad protective immunity (3, 4) .
One of the two licensed vaccines contains an FHbp sequence from variant groups 1 and 3 and was shown to elicit broad protective immunity against genetically diverse meningococcal strains (3, 5, 6) . The second licensed vaccine contains FHbp in variant group 1 and three other antigens capable of eliciting protective antibodies (7, 8) . Other strategies to increase the breadth of protection were to engineer FHbp antigens containing epitopes from different sequence variants (9) (10) (11) .
FHbp sequence variants in variant group 2 are prevalent among invasive strains in Europe (12) and North America (ID 19) (13) and Africa (ID 22) (14) . These two sequence variants were reported to have low thermal stability for the amino-(N-) terminal domain (15, 16) , whereas FHbp from variant groups 1 and 3 had high thermal stability (15, 17, 18) . The relatively low thermal stability for FHbp variant group 2 proteins was suggested to limit the vaccine potential of these variants (15) . In the present study, we used sequence alignments and the known 3D structure of FHbp (19) to identify two amino acid residues in FHbp variant group 1 that were important for thermal stability. Using this information, we engineered a mutant FHbp in variant group 2 that had increased thermal stability and determined its structure at high resolution. The mutant antigen had increased affinity for protective monoclonal antibodies (MAbs) and has the potential to improve next-generation FHbp vaccines.
Results
Thermal Stability of Natural FHbp Sequence Variants. A stable FHbp variant (ID 1 in variant group 1) unfolded with two thermal transitions (Fig. 1A) , which corresponded to the N-and carboxyl-(C-) terminal domains (17) . The transitions had midpoint (T m ) values of Significance Factor H binding protein (FHbp) is a component of two vaccines recently licensed for prevention of sepsis and meningitis caused by meningococci. FHbp is antigenically variable, and certain sequence variants have low thermal stability. Two amino acid substitutions stabilized a less stable FHbp variant by 21°C, and the high-resolution crystal structure of the stabilized FHbp antigen showed that the two new residues mediated multiple electrostatic interactions. The two substitutions increased the affinity for monoclonal antibodies specific for different regions of FHbp and increased binding to the mutant expressed on the surface of meningococci. The stabilized FHbp antigen has the potential to improve the immunogenicity of meningococcal vaccines containing recombinant FHbp or native outer membrane vesicles.
69.1 and 84.7°C (Table S1 ). A less stable FHbp variant (ID 22 in variant group 2) also unfolded with two transitions (Fig. 1D) , but with T m values of 38.5 and 82.3°C (Table S1 ). The enthalpy change (ΔH) for the N-terminal domain of the variant group 2 protein also was lower than the variant group 1 protein (12 and 96 kcal/mol). Whereas the T m and ΔH values for the C-terminal domain were similar for the two proteins, the stability of the N-terminal domain in the variant group 2 protein was lower, both in terms of transition temperature (ΔT m = 30.6°C) and enthalpy (ΔΔH = 83 kcal/mol).
To assess whether the thermal stability of the N-terminal domain was low for other variant group 2 proteins, we examined two additional sequence variants, ID 19 and 77 (Fig. S1 ). FHbp ID 19 had a T m value of 40.6°C and a ΔH of 16 kcal/mol for unfolding of the N-terminal domain. FHbp ID 77 had a T m value of 57.8°C and a ΔH of 34 kcal/mol. Although the stability of ID 77 was higher than ID 22, the stability of ID 77 was low compared with ID 1 in variant group 1 (Table S1 ). Using a multiple sequence alignment of three FHbp amino acid sequences from each of variant groups 1 and 2, we identified 25 differences within the N-terminal domain (Fig. S2 ). Of these, seven were nonconservative differences. Based on the locations and interactions of these seven residues in the crystal structure of FHbp (19), we identified two positions, 130 and 133, that we hypothesized to confer stability in the variant group 1 proteins.
Reciprocal Substitutions in FHbp Variant Groups 1 and 2. To test whether these two amino acid residues contributed to the stability of FHbp, we replaced each of the two residues in a stable FHbp variant (ID 1 in variant group 1) with the corresponding residue from less stable variants in variant group 2. The R130L substitution in FHbp ID 1 decreased the T m value of the N-terminal domain by 4.0°C, whereas there was little effect on the C-terminal domain (Fig. 1A and Table S1 ). The D133G substitution decreased the T m of the N-terminal domain by 10.4°C (Fig. 1B) . The R130L/D133G double mutant showed an effect that was slightly more than additive, with a T m that was 16.3°C lower than the wild-type (WT) protein (Fig. 1C) .
We further reasoned that the converse amino acid residue changes might stabilize FHbp in variant group 2. We chose FHbp ID 22, as this sequence variant was prevalent in invasive isolates from Africa (14, 20) and the immunogenicity of vaccines containing FHbp ID 22 previously had been tested in mice (6, 14, 16, 21) . The L130R substitution increased the T m of the N-terminal domain by 7.7°C (Fig. 1D) . The G133D substitution increased the T m by 16.6°C (Fig. 1E) . The L130R/G133D double mutant showed an effect that was slightly less than additive, with a T m that was increased by 20.9°C compared with the WT protein (Fig. 1F ). Whereas the ΔH values for the C-terminal domain were similar, the ΔH values for the N-terminal domain of the G133D single and L130R/G133D double mutant were considerably higher (97 and 56 kcal/mol) than for the WT (12 kcal/mol; Table S1 ).
Structural Basis for Increased Stability of the FHbp Antigen. To elucidate the structural basis for the increased stability of the FHbp ID 22 L130R/G133D double mutant, we crystallized the protein and determined its X-ray structure to 1.6 Å resolution [Protein Data Bank (PDB) ID 4Z3T]. We solved the structure using molecular replacement with a homology model of FHbp ID 22 (21) . The crystals were in space group P2 1 with two FHbp molecules in the asymmetric unit. We refined the model to an R work of 0.194 and an R free of 0.231 with good geometry; the data and refinement statistics are shown in Table S2 . The structure of one of the two molecules (chain A) and the positions of the two substituted residues are shown schematically ( Fig. 2A) . The electron density map was interpretable for residues 7-255 in chain A and 12-23 and 31-254 in chain B. Based on a superposition of the two chains, the rms deviation was 0.20 Å, and the largest backbone differences were 1-2 Å in the regions of residues 140 and 200, which were sites of crystal contacts.
There was clear electron density in the region of the two substituted residues (Fig. 2B ). The amino acid substitutions were confirmed by calculating a simulated annealing omit map from a model excluding the side chains of residues 130 and 133 (Fig.  2C ). Residue R130 mediated ionic and H-bonding interactions with R80 and E92 (Fig. 2D ). Residue D133 formed hydrogen bonds with three backbone nitrogen atoms (residues 37-39) and a fourth H bond with the side-chain hydroxyl group of S39 (Fig.  2E ). Both sets of interactions anchored regions that were distant in the primary sequence, which collectively served to stabilize the N-terminal domain. (22), bound ∼2.6-fold better to the double mutant than to the WT protein (i.e., the concentration of MAb needed to obtain an optical density of 2.0 was 2.6-fold lower for the mutant than for the WT; Fig. 3A) . Similarly, MAb JAR 41, which also recognizes an epitope in the N-terminal domain of FHbp (23), bound approximately (Table S1 ). Data are shown for one of two to three experiments.
threefold better to the double mutant (Fig. 3B) . Binding of a third MAb, JAR 31, which recognizes an epitope that is at least partially in the C-terminal domain of FHbp, was similar for the WT and double mutant (Fig. 3C) . Thus, the stabilization of epitopes appeared to be specific for those residing in the N-terminal domain.
To assess whether the stabilization of epitopes was due to increased affinity of the MAbs for FHbp, we also measured binding of the MAbs to FHbp by surface plasmon resonance (SPR). MAbs JAR 4 and JAR 41 had affinities for the double mutant that were 2.4-and 1.8-fold higher than for the WT FHbp. The dissociation constants (K D ) were significantly different (P ≤ 0.004; Table 1 ). In contrast, MAb JAR 31 had similar affinity for the WT and double mutant (P = 0.26). The higher affinities for the double-mutant protein partially resulted from differences in the off-rates for antibody binding (k d ; Table 1 ).
Binding of human FH decreases FHbp immunogenicity (24) (25) (26) , and FHbp mutants with decreased binding of FH elicit higher protective antibody responses in human FH transgenic mice (16, 24, 27) . Because R130 is an FH binding residue in variant group 1 proteins (28), we tested binding of human FH to the doublemutant FHbp. By ELISA, FH bound ∼17-fold less to the double mutant than to the WT protein (Fig. S3A) . A control Penta-His MAb, which was specific for the C-terminal His 6 tag, bound similarly to the two recombinant proteins (Fig. S3B) . We further characterized the affinity of FH for FHbp by SPR by capturing FH and injecting FHbp as the analyte. The ID 22 WT had a dissociation constant (K D ) of 17.7 ± 1.2 nM, whereas the double mutant had a K D of 118.0 ± 10.5 nM (P = 0.0007). Representative sensorgrams are shown in Fig. S3 C and D.
To determine whether the FHbp epitopes were stabilized in vivo, we constructed isogenic mutant meningococcal strains expressing an FHbp ID 22 WT or double-mutant protein on their surface. By flow cytometry, MAb JAR 4 showed significantly higher binding to the strain with the double mutant compared with the strain with the WT protein. The double mutant had a mean median fluorescence intensity (MFI) of 926 ± 59, compared with the WT with an MFI of 398 ± 13 (Fig. 4A) . Binding of MAbs JAR 41 and JAR 31 showed more subtle but reproducibly higher binding to the double mutant (Fig. 4 B and C) . As a control, we tested a MAb that recognizes an unrelated surface protein, PorA, which bound similarly to the two strains (Fig. 4D) . Calculation of the means and SE of triplicate measurements indicated that the differences in binding of the anti-FHbp MAbs to the WT and double mutant were significant (P ≤ 0.0015; Fig. 4 E-G) and paralleled those measured to the recombinant protein by SPR.
Discussion
Meningococcal FHbp vaccine antigens in variant groups 1 and 3 were reported to be stable (15, 17, 18) , whereas FHbp in variant group 2 was unstable (15, 16) . In the present study, we used multiple sequence alignments and a known crystal structure of FHbp in variant group 1 (19) to identify L130 and G133 as residues that might explain the lower thermal stability of FHbp variant group 2. The crystal structure of FHbp (ID 1 in variant group 1) contains a salt bridge network that includes residues E44, R80, E92, and R130, and replacement of any of these residues with alanine decreases the stability of the N-terminal domain. In contrast, the variant group 3 proteins contain polar and hydrophobic residues at the corresponding positions (G44, Q80, N92, and L130). The variant group 2 proteins are natural chimeras, with residues 1-93 derived from a variant group 1 lineage and residues 94-255 derived from a variant group 3 lineage (29) . The chimeric nature of the N-terminal domain (residues 1-136) in variant group 2 proteins appears to compromise its stability. Residues 130 and 133 reside at the interface between the two portions of this hybrid domain (Fig. S4A) . The low thermal stability for the N-terminal domain of FHbp in variant group 2 was suggested to limit its usefulness as a vaccine antigen (15) .
To overcome this potential limitation, we engineered an FHbp antigen in variant group 2 with substantially increased thermal stability and determined its crystal structure at high resolution. To date, crystal structures have been reported for FHbp from variant group 1 alone (19) and in a complex with a fragment of human FH (28) and FHbp from variant group 3 in a complex with the FH fragment (15) . Previous attempts to crystallize a WT FHbp variant group 2 protein resulted in the structure of a proteolytic fragment containing only the C-terminal domain (15) . Thus, the structure of the double mutant FHbp reported here is the first structure of an intact FHbp antigen in variant group 2. Overall, the structure of the double mutant showed similarity to that of FHbp ID 1 (19) , with a rms deviation for backbone atoms of 0.46 Å (Fig. S4B) . The main differences in backbone conformations were in the 80s loop (∼7 Å shift), the 210s loop (∼3 Å), and three other peripheral loops (∼2 Å), all of which were regions involved in contacts between adjacent molecules in the crystal lattice.
In the crystal structure of the FHbp double mutant, one of the two substituted residues, R130, was involved in a salt bridge network with E44, R80, and E92 that was similar to the network in FHbp ID 1 (Fig. S4C) ; however, there were slight differences in the side chain rotameric conformations of E92 and R130. The second substituted residue, D133, exhibited similar conformations in the two structures. Thus, by substitution of two amino acid residues in ID 22 with those present in ID 1, we recreated nearly the same atomic interactions and increased the thermal stability by 21°C. This was possible despite considerable amino acid sequence divergence between the two proteins (69% overall) and in particular in the region flanking 130-133 (Fig. S2) .
FHbp mutants with decreased binding of human FH were shown to have enhanced immunogenicity in human FH transgenic mice (15, 16, 24, 27) . The stabilized double-mutant FHbp had approximately sevenfold lower affinity for human FH than the WT FHbp (Fig. S3) . Residue R130 is known to stabilize the interaction of FHbp ID 1 with human FH (15, 28) ; therefore, we did not expect that the introduction of R130 in ID 22 would destabilize the interaction with FH. In the structure of FHbp ID 1 in a complex with a fragment of human FH, FHbp residue R130 mediates H bonds with two FH tyrosine hydroxyl groups, whereas D133 is ∼7 Å from the closest atoms in FH (Fig. S4D) . Because R130 and D133 adopt similar side chain rotameric conformations in the structures of the double-mutant FHbp and the FHbp-FH fragment complex, the decrease in affinity for FH in the double mutant may be due to subtle structural changes near the mutation sites. The observation of decreased affinity for the mutant despite having residues R130 and D133 (as in FHbp ID 1 in variant group 1) supports previous data indicating that FHbps from different variant groups have different binding modes for FH (15, 21) .
A comparison of the structures of a fragment of human FH in complexes with FHbp ID 1 in variant group 1 (28) and ID 28 in variant group 3 (15) indicates that the FH interaction surfaces are in similar locations but that the residues involved differ. Further, FH has different affinities for FHbp from each of the three variant groups as measured by SPR, and through analysis of site-specific mutants, the binding hotspots differ (15) . Although a sevenfold decrease in FH binding for the stabilized mutant might not be sufficient for an optimal increase in FHbp immunogenicity in the presence of human FH, in future studies additional amino acid substitutions (e.g., D211A, T221A, or others) (15, 16, 21) could be incorporated to obtain stable mutants with very low FH binding and optimal immunogenicity. This approach has the further advantage that the stabilizing substitutions might compensate for any possible effects of the substitutions that decrease FH binding on destabilizing protective epitopes.
As described in the opening paragraphs of this article, an investigational meningococcal vaccine contains a fusion of FHbp molecules in variant groups 1-3 (11) . A second experimental vaccine employs native outer membrane vesicles that contain two overexpressed FHbp variants, one each from variant groups 1 and 2 (30) . All three variant group 2 proteins tested to date have low thermal stability compared with proteins in variant groups 1 and 3 ( Fig. S1) (15) . The same amino acid substitutions that were introduced to stabilize FHbp ID 22 might also increase the stability of other FHbp variant group 2 proteins, which exist in two different modular groups based on the chimeric structure noted above (29) .
Using three complementary approaches, we demonstrated that the stabilized double-mutant FHbp had higher binding of two cross-reactive MAbs. In ELISA, SPR, and flow cytometry experiments, MAbs JAR 4 and JAR 41 exhibited significantly higher binding to the double mutant than to the WT FHbp (Figs. 3 and 4 and Table 1 ). These experiments highlight the conformational integrity of the stabilized double mutant, both in the form of the recombinant protein purified from Escherichia coli as well as the native, lipidated protein expressed on the surface of meningoccocci. Because residues involved in the epitopes recognized by MAbs JAR 4 and JAR 41 are located outside the FH binding site and neither of these MAbs inhibits binding of FH to FHbp, the effect of the amino acid substitutions on MAb epitopes appears to be indirect via stabilization of the N-terminal structural domain.
The unfolding of the N-terminal domain of FHbp and several of the variant group 2 proteins tested occurs at temperatures (38.5-40.6°C) that are only slightly higher than the physiological temperature, and therefore, some FHbp epitopes may be labile at this temperature. A stabilized variant group 2 protein is predicted to present epitopes and elicit protective antibody responses that are as high or higher than the WT protein. The stabilized mutant also might facilitate the production and formulation of vaccines containing certain recombinant FHbp variants. Finally, a stabilized FHbp mutant might have increased surface expression and/or better presentation of epitopes in meningococci, which could enhance the immunogenicity of native outer membrane vesicle vaccines.
Materials and Methods
Site-Specific Mutagenesis. Directed mutagenesis was carried out using the pET21b-FHbp ID 1 (4) or ID 22 (6) plasmids as templates. PCR amplification and ligation was carried out using the procedures described in the Phusion Site-Directed Mutagenesis Kit (Thermo Scientific). The sequences of the oligonucleotide primers are listed in Table S3 .
Protein Expression and Purification. FHbp was expressed from pET21-based plasmids in E. coli strain BL21(DE3). Lysis was performed with three freeze/thaw cycles in the presence of 0.1 mg/mL each of lysozyme, DNase (Sigma), and RNase A (Qiagen) in 50 mM NaPO 4 , 500 mM NaCl, 20 mM imidazole pH 7.4. The clarified lysate was loaded on a HiTrap Chelating HP column (5 mL, GE Life Sciences), and FHbp was eluted with a linear gradient of imidazole. Fractions containing FHbp were dialyzed against 25 mM 2(N-morpholino)ethane sulfonic acid, 150 mM NaCl, pH 5.5, and loaded on a HiTrap SP HP column (5 mL, GE Life Sciences). FHbp was eluted with a linear gradient to 750 mM NaCl. The protein concentration was measured by absorbance at 280 nm (Nanodrop 1000, Thermo Scientific), using the molar extinction coefficient calculated from the amino acid sequence using ProtParam (31).
ELISA. Binding of human FH and anti-FHbp MAbs to purified FHbp was performed as described (9) . Briefly the wells of a microtiter plate were coated with 2 μg/mL of purified recombinant FHbp in PBS. After blocking with PBS containing 0.01% (wt/vol) sodium azide and 1% (wt/vol) BSA, serial dilutions of purified human FH, anti-FHbp MAbs, or a control Penta-His MAb (Qiagen) were added and incubated at room temperature for 1 h. Bound FH was detected with sheep anti-FH (1:7,000; Abcam) and donkey anti-sheep IgG conjugated to alkaline phosphatase (1:5,000; Sigma). Bound MAbs were detected with goat anti-mouse IgG conjugated to alkaline phosphatase (1:5,000; Sigma). The ELISAs were developed using paranitrophenyl phosphate substrate (1 mg/mL; Sigma), and the optical density at 405 nm (OD 405 nm ) was measured after 30 min at room temperature. Relative binding was calculated as the ratio in the concentration of FH or MAb needed to obtain an OD 405 nm of 2.0 for WT versus mutant FHbp. FH and mAb binding was tested in at least three experiments, and the means and 2 SE are shown from two experiments, each performed in triplicate.
Differential Scanning Calorimetry. Thermal stability of FHbp was measured using a VP-DSC instrument (Microcal). The protein was dialyzed against PBS, and dialysis buffer was used as the reference solution. The protein concentration was 0.5 mg/mL, the scan rate was 60°C/h, and the passive feedback mode was used. The data were analyzed using a non-two state model using Origin 5.0 software (Microcal). Representative data are shown from two to three experiments. Transition midpoint (T m ) and enthalpy change (ΔH) values and associated errors reported are derived from curve fitting to the data from one experiment.
Crystallization and Structure Determination. FHbp ID 22 double-mutant protein was dialyzed against 10 mM Tris·Cl, 25 mM NaCl, pH 7.0, and concentrated to 9.7 mg/mL. Crystals were grown by vapor diffusion in hanging drops in 27% (wt/vol) PEG 3,350, 0.1 M Tris·Cl, pH 9.5, and 0.25 M MgCl 2 . X-ray diffraction data were collected on beamline 5.0.1 at the Advanced Light Source, Lawrence Berkeley National Laboratory (λ = 0.977 Å, 100 K). Data were reduced with Mosflm/Scala, and the structure was solved by molecular replacement using MolRep (32) and a homology model of FHbp ID 22 (21) . The structure was refined using Phenix (33) ; noncrystallographic symmetry restraints were used in the earlier rounds of refinement. Model building was performed with Coot (34). The refined structure contained backbone dihedral angles that were 97% in favored, 3% in allowed, and 0% in outlier regions. The atomic coordinates and reflection data are deposited in PDB (ID code 4Z3T).
SPR. Kinetic parameters for binding of anti-FHbp MAbs to FHbp were determined using a Biacore X-100 Plus instrument (GE Life Sciences). We immobilized 14,000 response units (RUs) of goat anti-mouse IgG Fc-specific antibody (Jackson ImmunoResearch) on a CM5 biosensor chip with an Amine Coupling kit (GE Life Sciences). For single-cycle kinetics, ∼500 RUs of murine anti-FHbp MAbs were captured, and five concentrations (1-100 nM or 3.16-316 nM) of FHbp analyte were injected. The MAbs used were JAR 4 (22, 35) , JAR 41 (23), and JAR 31 (6) . For measuring affinity of FH for FHbp, a goat anti-human FH antibody (Complement Technologies) that had been affinity purified was amine coupled to a CM5 chip. This antibody was used to capture purified human FH, and FHbp analyte was injected at concentrations from 1 to 100 nM. Data were analyzed with a 1:1 binding model using Biacore X100 Evaluation software. Each binding assay was performed in at least two duplicate or triplicate experiments, and the means and SE of three to four measurements are given.
Detection of Mutant FHbp on the Surface of Meningococci. Two isogenic mutant meningococcal strains were constructed from strain H44/76. The native FHbp ID 1 gene was replaced by homologous recombination with FHbp ID 22 (WT or double mutant) adjacent to an ermC cassette (25, 36) . Erythromycin-resistant mutants were selected and verified by DNA sequencing of the fhbp gene. Bacteria were grown in Frantz medium (37) to an OD 620 nm of 0.6 and washed in Dulbecco's PBS (Corning CellGro) containing 1% (wt/vol) BSA (Equitech Bio). FHbp was detected with murine MAbs to FHbp (see SPR) or PorA P1.7 (MN14C11.6) (38), followed by goat anti-mouse IgG conjugated to AlexaFluor 488 (Life Technologies). The fluorescence was read on a Fortessa flow cytometer (BD Biosciences), and the data were analyzed with FlowJo X software (TreeStar). Binding was tested in three experiments, and data are shown from an experiment performed in triplicate.
Statistical Analyses. The means and SEs of ELISA and SPR and flow cytometry data were calculated with Prism 6.0f (GraphPad) from three to six replicates. Statistical tests were performed using parametric t tests using Prism. Twotailed P values ≤ 0.05 were considered to be statistically significant.
